Michele Gambardella1*, Antonino Crocamo1, Vincenzo Barlotti1, Augusto La Penna2, Gerarda Pirofalo3 and Giovanni D’Arena4
Apergillosis in immunocompetent critical patients has increased incidence over the past two decades. Patients at risk include those with systemic steroid therapies and deteriorate pulmonary functions (COPD). Hemoptysis is a devastating complication of pulmonary aspergillosis reported in 28.9% of cases.
Поделиться этой статьей